Roche announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of adult and pediatric patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced recurrent solid tumors. Rozlytrek is the first tumor-agnostic medicine to be approved in Japan that targets NTRK gene fusions, which have been identified in a range of hard-to-treat solid tumor types, including pancreatic, thyroid, salivary gland, breast, colore...